Introduction {#S0001}
============

Ovarian cancer is one of the leading causes of cancer deaths in women. Due to the lack of any specific tumor marker, the diagnosis of this disease usually happens in advanced stages leading to high mortality rate. Although, the increased level of CA125 is considered to be a diagnostic marker (in about 80% of cases), but it is still not reliable and usually increases at very late stages. Since no suitable diagnostic and curative therapy is available, there is a high demand for finding novel tumor markers in this malignancy both for diagnostic and therapeutic purposes.

Gene expression profiling of ovarian carcinoma patients in early and late stages or with low malignant potential has shown a nearly four-fold increase of *SORT1* gene expression ([@CIT0001]).

The human *SORT1* gene consists of 22 exons located on the short arm of chromosome 1 (1p21.3-p13.1) encoding a type I receptor of 831 amino acids with a molecular weight of 95--100 *kDa*. Seven non-coding transcript variants for this gene have also been reported.

*SORT1* is expressed at gene level in heart, brain, placenta, skeletal muscle, spinal cord, thyroid, and testis ([@CIT0002]). Its expression, however, has never been reported in normal ovary. Sortilin 1 is a member of family of Vps10p-domain receptors. It is known as a multi-ligand molecule and such proteins as lipoprotein lipase (LPL), Neurotensin 3 (NT3), Receptor associated protein (RAP), proNGF, and thyroglobulin are among its potential ligands ([@CIT0002], [@CIT0003]--[@CIT0005]).

The function of sortilin 1 varies depending on its location and the presence of its ligands. Sortilin 1 acts as a sorting receptor when it is expressed in trans-golgi network and also as a clearance receptor when it is expressed on cell surface ([@CIT0002], [@CIT0003]--[@CIT0005]).

The role of sortilin 1 and NT3 as its ligand in cancer cell growth has previously been reported ([@CIT0006]). Although, sortilin 1 as a type I receptor lacks the necessary domains involved in signaling, but is an essential part of a receptor complex for pro-NGF induced neural cell death ([@CIT0005], [@CIT0007]).

The four-fold overexpression of *SORT1* in ovarian carcinoma together with its driving role in cancer cell growth brings forward the potential involvement of this protein in the pathobiology of this disorder. To test this hypothesis, we studied the expression of sortilin 1 in 15 ovarian carcinoma patients both at gene and protein levels. Sortilin 1 was expressed in all 15 ovarian carcinoma tumor tissues as well as related cell lines, while no expression of this molecule in non-malignant ovarian tissue was found. The expression of sortilin 1 in ovarian carcinoma patients may represent a crucial role of this protein in tumorigenesis driving machinery.

The four-fold overexpression of *SORT1* in ovarian carcinoma together with its driving role in cancer cell growth brings forward the potential involvement of this protein in the pathobiology of this disorder. To test this hypothesis, we studied the expression of sortilin 1 in 15 ovarian carcinoma patients both at gene and protein levels. Sortilin 1 was expres-sed in all 15 ovarian carcinoma tumor tissues as well as related cell lines, while no expres-sion of this molecule in non-malignant ovarian tissue was found. The expression of sortilin 1 in ovarian carcinoma patients may represent a crucial role of this protein in tumorigenesis driving machinery.

Materials and Methods {#S0002}
=====================

Patients and tissue samples {#S20003}
---------------------------

Ovarian tissue samples were obtained from patients at Imam Khomeini Hospital. After a consent letter was signed by each patient, all the aspects of this study were approved by the Avicenna Local Ethics Committee. After surgical resection, each fresh tumor specimen was immediately divided into two portions: one portion was instantly frozen in liquid nitrogen and the other was OCT (Optimal Cutting Compound) embedded using Jung freezing medium (Leica Instruments, Nussloch, Germany) for immunohistochemical investigations.

Fifteen malignant ovarian tissue samples including papillary serous carcinomas (n=9; mean age 48.3±16.08 *yr*), endometrioid carcinoma (n=1; age 39), mucinous carcinomas (n=2; age 59 and 70 *yr*s), clear cell carcinoma (n=1; age 45 *yr*), germ cell tumor (n=1; age 28 *yr*), and sex cord-stroma tumor (n=1; age 22 *yr*) were investigated. A total of six non-malignant ovarian tissues (mean age 45.3±4.2 *yr*) served as control group ([Table 1](#T0001){ref-type="table"}). Tissue sections made from each sample, stained with Hematoxylin and Eosin (H&E) and examined by two independent pathologists to confirm the pathological state of each sample.

###### 

Expression of sortilin 1 and phenotypic characterization of 15 ovarian carcinoma patients compared to the normal ovary tissues from 6 healthy individuals

  Patients     Morphology              Type of differentiation      Age (*yr*)   Stage   CA125 level (*U/ml*)   Level of differentiation   RT-PCR (nested) and Western blot
  ------------ ----------------------- ---------------------------- ------------ ------- ---------------------- -------------------------- ----------------------------------
  **T4**       Epithelial              Serous cyst adenocarcinoma   40           NA      NA                     NA                         \+
  **T5**       Epithelial              Serous cyst adenocarcinoma   48           IV      38.6                   NA                         \+
  **T7**       Sex cord-stroma         Granulosa cell tumor         22           NA      NA                     NA                         \+
  **T9**       Epithelial              Serous cyst adenocarcinoma   23           III     66.4                   NA                         \+
  **T10**      Epithelial              Clear cell                   45           III     183                    NA                         \+
  **T14**      Epithelial              Serous cyst adenocarcinoma   66           IV      1890                   Moderate                   \+
  **T15**      Epithelial              Serous adenocarcinoma        33           I       \>1000                 Well                       \+
  **T18**      Epithelial              Serous adenocarcinoma        66           NA      \>1000                 Well /moderate             \+
  **T19**      Epithelial              Endometrioid                 39           III     48                     Moderate                   \+
  **T22**      Epithelial              Serous adenocarcinoma        69           II      2490                   Moderate                   \+
  **T25**      Epithelial              Mucinous                     59           NA      124                    NA                         \+
  **T32**      Epithelial              Serous cyst adenocarcinoma   50           NA      448                    NA                         \+
  **T34**      Germ cell               Yolk sac tumor               28           NA      31.9                   NA                         \+
  **T37**      Epithelial              Mucinous                     70           NA      NA                     NA                         \+
  **T39**      Epithelial              Serous adenocarcinoma        40           III     NA                     Well                       \+
  **Normal**   Non-malignant tissues   --                           40--49       --      NA                     --                         Negative (6 out of 6)

NA: not assigned

Cell lines {#S20004}
----------

The human ovarian carcinoma cell lines ([Table 2](#T0002){ref-type="table"}) were cultured in RPMI 1640 (**Gibco**, **Invitrogen**, USA), containing 10% fetal bovine serum (**Biochrom AG**, **Berlin**, Germany), 100 *units/ml* penicillin (**ICN** Bio-medicals, Ohio, USA), and 100 *µg/ml* strepto-mycin (Sigma, St Louis, MO). All cell lines were cultured at 37 *°C* in a humidified incubator with 5% CO~2~ atmosphere.

###### 

Expression of sortilin 1 in ovarian cancer cell lines

  Cell line        Morphology   Western blot   RT-PCR   Reference
  ---------------- ------------ -------------- -------- --------------------
  **CAOV-4**       Epithelial   \+             \+       ATCC (HTB-76)
  **A2780S**       Epithelial   \+             \+       NCBI (C461)
  **A2780CP**      Epithelial   \+             \+       NCBI (C454)
  **2008/C13.R**   Epithelial   \+             \+       NCBI (C446)
  **OVCAR-3**      Epithelial   \+             \+       ATCC **(**HTB-161)
  **SKOV-3**       Epithelial   \+             \+       ATCC (HTB-77)

NCBI; National Cell Bank of Iran, ATCC; American Type Culture Collection

RNA extraction and cDNA synthesis {#S20005}
---------------------------------

Total RNA was extracted from cell lines and tissue samples using RNA-Bee reagent (BioSite, Täby, Sweden) according to the manufacturer\'s instruction. The quality of the RNA samples was determined by agarose gel electrophoresis after staining with ethidium bromide, and visualization under UV light. Total RNA was unfolded at 65 °*C* for 10 *min*. cDNA was then synthesized using 5 *µg* of total RNA in 20 *µL* reaction mixture consisting of 4 *µL* of 5x reaction buffer, 1 *µL* of 10 *mM* dNTPs, 1 *µL* of 10 *pmol/mL* random hexamers (N6), and 200 *U* *M-MuLV* reverse transcriptase (Fermentas GmbH, St. Leon-Rot, Germany). The reaction mixture was incubated at 42 *°C* for 45 *min*.

RT-PCR amplification of SORT1 {#S20006}
-----------------------------

RT-PCR amplification was performed using *SORT1* gene (g.b. NM_002959) specific primers of "CAGTCCAAGCTATATCGAA GTGAGG" as sense and "AAGATGGTGTT GTCTGATCCCCATTT" as antisense (Operon, Köln, Germany). Briefly, 25 *µL* reaction mixture of PCR was prepared using 2.5 *µL* 10*x* buffer, 3 *µL* 25 *mM* MgCl~2~, 1 *µL* dNTPs (10 *mM*), 5 *pmol* of each primer, 1 Unit Taq DNA polymerase (Roche, Germany) and 1 *µl* template cDNA. PCR was then followed by 35 cycles (for *SORT1*) or 30 cycles (for β-actin) at 92 °*C* for 30 *sec*, 60 °*C* for 30 *sec*, and 72 °*C* for 30 *sec* leading to a 383 *bp* *SORT1* or 155-*bp* β-actin amplicons. To ensure the specificity of primers, some of the *SORT1* PCR products were cloned into pGEM-T easy vector (Promega, Madison, WI) and were subjected to sequencing.

Due to the poor quality of RNA prepared from some tissue samples, nested-PCR was carried out for detection of *SORT1* gene in ovary tissues using "GTTAACAGCAGAG GTGTCTGGAG" as sense primer and "AA ACATACTGCTTTGTGGATTTC" as antisense primer. Briefly, 1 *µl* of RT-PCR product was added to a new 24 *µl* reaction mixture containing 2.5 *µl* 10x PCR buffer, 3 *µl* 25 *mM* MgCl2, 1 *µl* 10 *mM* dNTPs, 5 *pmol* of each primer, and 1 *Unit Taq* DNA polymerase. Nested PCR was performed for 20 *cycles* generating an amplicon of 225 *bp*. PCR products were finally visualized by running agarose gel electrophoresis containing ethidium bromide.

Western blotting {#S20007}
----------------

Tissues and cell lines were lysed in lysis buffer containing 2% Triton X-100, 10 *mM* Tris, pH 7.4, 100 *mM* NaCl, 1 *mM* EDTA, 1 *mM* NaF, 20 *mM* Na~4~P~2~O~7~, 1% glycerol, 0.1% sodium dodecyl sulfate (SDS), and 1% protease inhibitor cocktail (Sigma) on crashed ice for 1 *hr*. The lysates were then centrifuged for 10 *min* (9300 *g*, 4 °*C*). The protein concentration of the supernatant was estimated by the Bradford method. Equal amounts of protein (30 *µg*) were run on 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) at 100 *V* for 2 *hr* under non-reducing condition.

After electrophoresis, resolved proteins were transferred onto PVDF (polyvinylidene difluoride) membranes (Millipore, Bedford, USA). The membranes were then blocked overnight at 4 °*C* with 5% nonfat milk in phosphate-buffered saline (PBS)-Tween 20 (0.15 *M* PBS pH 7.4, 0.1% Tween 20). All additional incubations were performed in PBS-Tween 20 supplemented with 5% nonfat milk (Merck, Darmstadt, Germany). Membranes were incubated with a rabbit polyclonal antibody against human sortilin 1 (Abcam, Cambridge, UK) at a concentration of 1 *µg/mL* for 1 *hr*. After 4 times of 15 *min* washings with PBS-Tween 20, membranes were incubated with a horseradish peroxidase (HRP)-conjugated sheep anti-rabbit immuno-globulin (Avicenna Research Institute, Tehran, Iran) as secondary antibody for 1 *hr* and washed as above.

To verify the relative amounts of protein in each lane, the level of β-actin as an internal control was measured with anti-β-actin monoclonal antibody (Sigma). Membranes were developed using the ECL detection system (GE Healthcare, Uppsala, Sweden) according to the manufacturer\'s instruction.

Immunohistochemistry (IHC) {#S20008}
--------------------------

Five *µm* sections of OCT-embedded ovary tissues were cut on a cryostat (Thermo-Shandon, UK), dried overnight, fixed in acetone for 2 *min* at −20 °*C* and kept at −70 °*C* until use. Slides were then thawed and washed three times (3×3 *min*) with Tris-Buffered Saline, pH 7.4 containing 5% bovine serum albumin (TBS-BSA). At the next step, the slides were blocked with 5% goat serum diluted in TBS-BSA for 30 *min* and incubated with 1:500 diluted primary anti-sortilin 1 polyclonal antibody (Abcam, Cambridge, UK) overnight at 4 *°C*. To confirm the specificity of the IHC staining, negative reagent control slides were incubated with TBS-BSA without any primary antibody (no-antibody control) or with pre-immune rabbit serum with the same IgG concentration. Following three washes, the slides were then incubated with 1:75 dilution of fluorescin isothiocyanate (FITC)-conjugated goat anti-rabbit IgG (Ray Biotech, Inc. GA, USA) for 45 *min*.

After washing with TBS-BSA, the nuclei were counterstained by 4',6-diamidino-2-phenylindole dihydrochloride (DAPI) (Cal-biochem, USA) at 1*µg/ml* for 5 *min*, then the slides were washed, mounted in PBS-glycerol 90% and examined under a fluorescence microscope (Olympus, Tokyo, Japan).

Results {#S0009}
=======

SORT1 gene expression {#S20010}
---------------------

Representative RT-PCR gel of ovarian carcinoma patients is shown in [Figure 1](#F0001){ref-type="fig"}. All ovarian carcinoma patients (n=15) expressed *SORT1* at the mRNA level ([Table 1](#T0001){ref-type="table"}). *SORT1* was also expressed in all six ovarian carcinoma cell lines ([Table 2](#T0002){ref-type="table"}). Non-malignant ovary, however, failed to express this gene (data not shown).

![*SORT1*-specific mRNA expression (nested RT-PCR) in ovarian cancer tissue samples. Lanes 1-9 tissue samples, -ve: Negative control PCR reaction without template, M: DNA size marker. The figure represents 9 experiments out of 15. The extra bands over 225 *bp* are due to the overload of primary PCR reactions](AJMB-1-125-g001){#F0001}

Sortilin 1 protein expression {#S20011}
-----------------------------

Western blot analyses of six ovarian carcinoma cell lines showed a band of 95--100 *kDa* as well as an extra band of 50 *kDa* ([Figure 2A](#F0002){ref-type="fig"}). Cell lysates from primary ovarian carcinoma tissues of different subtypes showed only a band of 95-100 *kDa* of sortilin 1 ([Figure 2B](#F0002){ref-type="fig"}). None of the non-malignant ovary samples expressed sortilin 1 at protein level ([(Figure 2C](#F0002){ref-type="fig"}).

![Western blot analysis of sortilin 1 using rabbit polyclonal anti-sortilin antibody under non-reducing conditions. A) All ovarian cancer cell lines exhibited expression of about 100 kDa sortilin 1 protein. \*A band of about 50 kDa was also expressed by these cell lines. B) Ovarian cancer tissue samples T7, T10, T14, T18, T19, T25, and T32 corresponding to patients in Table I selected based on their differentiation. Human brain (HB) cell lysate served as positive control. C) Lanes 1-6 representing non-malignant ovarian tissue samples. Lane 7 represents human brain cell lysate. β-actin expression was used as an internal loading control](AJMB-1-125-g002){#F0002}

To confirm the expression and localization of sortilin 1 in tumor samples, we performed indirect immunofluorescence staining on 7 malignant ovarian tissue samples and 5 normal ovaries. The positive staining was only observed in the cell membrane of malignant epithelial cells. Consistent with the results obtained by Western blotting, the ovarian carcinomas (four of seven specimens) expressed sortilin 1 mainly localized to cell surface rather than ER-Golgi compartment in immunohistochemistry & tainins. Three out of seven ovarian carcinoma samples showed lower levels of sortilin 1 in immunofluorescence experiments. Similar to Western blot results, no sortilin 1 expression was observed in normal ovary tissue sections. One representative out of seven immunofluorescence experiments is shown in [Figure 3](#F0003){ref-type="fig"}.

![Immunofluorecense staining of sortilin 1 in ovarian carcinoma tissue (T15) using rabbit anti-sortilin 1 polyclonal antibody. The enlarged part clearly shows the cell surface expression of sortilin 1. The figure represents one experiment out of seven](AJMB-1-125-g003){#F0003}

Discussion {#S0012}
==========

The functional roles of neuropeptides (NT) and their receptors in cancer cell growth are now well established. The growth effect of sortilin 1 as neurotensin-3 receptor (NTR-3) in prostate, colon, and pancreatic cancer cell lines strongly suggests the involvement of this protein in cell growth ([@CIT0008]). Sortilin 1 was also expressed in a panel of breast cancer cell lines (our unpublished data). It seems that the expression of sortilin 1 is not restricted to ovarian carcinoma and it might be also expressed in other solid tumors. This may signify more important function of this receptor in cancer development.

The functional roles of neuropeptides (NT) and their receptors in cancer cell growth are now well established. The growth effect of sortilin 1 as neurotensin-3 receptor (NTR-3) in prostate, colon, and pancreatic cancer cell lines strongly suggests the involvement of this protein in cell growth ([@CIT0008]). Sortilin 1 was also expressed in a panel of breast cancer cell lines (our unpublished data). It seems that the expression of sortilin 1 is not restricted to ovarian carcinoma and it might be also expressed in other solid tumors. This may sig-nify more important function of this receptor in cancer development.

In our study, the cell lysates from all ovarian cancer tissues and cell lines but not from non-malignant ovary tissues, showed expression of 95-100 *kDa* sortilin 1 protein indicating an ectopic expression. Interestingly, a 50 *kDa* band was only observed in ovarian carcinoma cell lines whereas it was absent in breast cancer cell lines (data not shown). This 50 *kDa* band may represent an unidentified isoform of sortilin 1 which requires further characterization.

Although, sortilin 1 is mainly localized to ER-Golgi apparatus, it is also expressed as a mature cell surface receptor ([@CIT0009]). Our immuno-fluorescence experiments showed that sortilin 1 is mainly expressed on tumor cell surface rather than ER-Golgi compartment. The surface expression of this protein may provide a more significant role for this protein in ERK signaling pathway ([@CIT0010]) leading to proliferation of cancer cells. Apparently, expression of sortilin 1 in ovarian cancer cells as a cell surface receptor does not induce apoptosis excluding its proapoptotic activity. This might be due to the lack of other co-receptors required for triggering apoptosis in ovary cancer cells and the absence of their signaling mediators (proNGF, proBDNF). It could be also due to structural differences in sortilin 1 expressed by cancer cells leading to impaired heterodimerization with other co-receptors (p75NTR) which is necessary for signal transduction. In general, the dual functional pro-apoptotic and anti-apoptotic roles of sortilin 1 must be considered in normal and pathogenic conditions.

Among patients enrolled in this study two patients had tumors with morphology of non-epithelial origin indicating that expression of sortilin 1 is not restricted to epithelial cells. Due to the lack of patient samples from early stages and also limited number of patients, it was not possible to correlate the expression level of sortilin 1 to the stage of the disease as well as to CA125 level or age of the patients. In this regard the expansion of the study in more patients is warranted.

Recent report shows that sortilin 1 is also expressed in thyroid epithelial cells capable of binding with high affinity to thyroglobulin, another evidence for sortilin 1 as a multi-ligand receptor ([@CIT0004]). This finding together with the expression of sortilin 1 in ovarian carcinoma may explain the 4% incidence of metastasis of ovarian carcinoma to thyroid glands, rich in thyroglobulin ([@CIT0011]) as well as the same incidence in brain metastases ([@CIT0012]).

Recent report shows that sortilin 1 is also expressed in thyroid epithelial cells capable of binding with high affinity to thyroglobulin, another evidence for sortilin 1 as a multiligand receptor ([@CIT0004]). This finding together with the expression of sortilin 1 in ovarian carcin-oma may explain the 4% incidence of metas-tasis of ovarian carcinoma to thyroid glands, rich in thyroglobulin ([@CIT0011]) as well as the same incidence in brain metastases ([@CIT0012]).

Altogether, ectopic expression of sortilin 1in ovarian carcinoma tissues, its absence in normal human ovary, its involvement in ERK signaling pathway ([@CIT0010]) as well as its restricted tissue expression in women makes it a potential candidate for developing more selective targeted therapy approach in patients with ovarian carcinoma. In this regard, generation of monoclonal antibodies capable of inducing apoptosis and also competing with sortilin 1 ligand binding site (Vps10p domain) is recommended.

Women with cancer may suffer from infertility after medical treatment. The current approach to protect reproductive capability in women with cancer is ovarian cortex cryo-preservation prior to any medical treatment and re-implanting the frozen ovary tissues after cancer therapy. Detection of sortilin 1, as a unique marker in the cryopreserved tissue for distinguishing malignant ovaries from non malignant ones before reimplantation may decrease the risk of relapse in these patients leading to regaining their reproductive capability.

To the best of our knowledge, this study is the first report describing ectopic expression of sortilin 1 in patients with ovarian carcinoma. Further functional impacts and structural characterization are needed to explore its potential role in the pathogenesis of ovarian carcinoma.
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